Crizotinib is an orally bioavailable agent belonging to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity. Crizotinib was approved For treatment of some non-small cell lung carcinoma (NSCLC) in the US, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and childre. Crizotinib inhibits the membrane receptor MET and activation of the MET signaling pathway, which may block tumor cell growth, migration and invasion, and tumor angiogenesis in susceptible tumor cell populations. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus) . For the detailed information about the solubility of Crizotinib (PF-2341066) in water, the solubility of Crizotinib (PF-2341066) in DMSO, the solubility of Crizotinib (PF-2341066) in PBS buffer, the animal experiment£¨test£© of Crizotinib (PF-2341066),the in vivo,in vitro and clinical trial test of Crizotinib (PF-2341066),the cell experiment£¨test£© of Crizotinib (PF-2341066),the IC50, EC50 and Affinity of Crizotinib (PF-2341066).